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Abstract 
Introduction: For chronic prosthetic joint infections (PJI), complete removal of the infected prosthesis is 
necessary in order to cure the infection. Unfortunately, a subgroup of patients is not able to undergo a 
revision surgery due to high surgical risk. Alternatively, these patients can be treated with antibiotic 
suppressive therapy (AST) to suppress the infection. Aim: To evaluate the efficacy and tolerability of 
AST. Methods: We retrospectively collected data (period 2009-2015) from patients with a PJI (of hip, 
knee or shoulder) who were treated with AST at the University Medical Center Groningen, the 
Netherlands. AST was defined as antibiotic treatment for PJI that was started after the usual 3 months 
of antibiotic treatment. The time of follow-up was defined from the time point AST was started. 
Treatment was considered as failed, when the patient still experienced joint pain, when surgical 
intervention (debridement, removal, arthrodesis or amputation) was needed to control the infection 
and/or when death occurred due to the infection. Results: We included 21 patients with a median age of 
67 years (range 21 - 88) and with a median follow-up of 21 months (range 3 - 81). Coagulase negative 
staphylococci (CNS) (n=6), S. aureus (n=6) and polymicrobial flora (n=4) were the most frequently 
found causative pathogens. Most patients with CNS and S. aureus were treated with minocycline (67%) 
and clindamycin (83%) as AST, respectively. Overall, treatment was successful in 67% of patients. Failure 
was due to persistent joint pain (n=1), surgical intervention because of an uncontrolled infection (n=3), 
and death due the infection (n=3). We observed a treatment success of 90% in patients with a ‘standard’ 
prosthesis (n=11), compared to only 50% in patients with a tumor-prosthesis (n=10). Also, treatment 
was successful in 83% of patients with a CNS as causative microorganism for the infection, compared to 
50% in patients with a S. aureus. Patients who failed on AST had a higher ESR in comparison to patients 
with a successful treatment (mean 73 ± 25SD versus 32 ± 19SD mm/hour (p = 0.007), respectively. 43% 
of patients experienced side effects and led to a switch of antibiotic treatment or a dose adjustment in 
almost all of these patients. Conclusions: Removal of the implant remains first choice in patients with 
chronic PJI. However, AST is a reasonable alternative treatment option in a subgroup of patients with a 
PJI who are no candidate for revision surgery, in particular in patients with a ‘standard’ prosthesis and/or 
CNS as the causative micro-organism. 
Key words: prosthetic joint infection, antibiotic suppressive therapy, side effects 
Introduction 
For patients with a chronic prosthetic joint 
infection (PJI), removal of the infected prosthesis via a 
one- or two-stage revision surgery is required to cure 
the infection. The chance to cure the infection depends 
on multiple factors, including the affected joint, the 









and several host-factors.1-4 In general, if the infection 
is considered as difficult to treat, a two-stage surgical 
revision is indicated. Overall, the current success rates 
of revision surgery are quite high, on average, around 
90% for both one-stage and two-stage procedures.1-4  
Unfortunately, this means that in roughly 10% of 
patients, re-infection occurs and re-revision surgery is 
needed. Multiple revision surgeries ultimately 
diminish the chance to cure the infection due to poor 
bone stock and soft tissue injury.5 As a result, 
complete removal of the prosthesis resulting in a 
Girdlestone situation, arthrodesis or lower-limb 
amputation is, in most cases, inevitable in order to 
eliminate the infection. Antibiotic suppressive 
therapy (AST) can be subscribed for these patients as 
alternative treatment to suppress the infection 
without removal of the prosthesis as long as possible, 
and to avoid these disabling surgeries. This 
conservative antibiotic treatment approach can also be 
applied in patients with a poor prognosis due to 
cancer, and in elderly patients or patients with severe 
comorbidity that are not vital enough to undergo 
revision surgery.  
Apart from its main benefit, i.e. avoidance of 
complex and potentially harmful surgery, important 
disadvantages of AST may include treatment failure 
and unmanageable antibiotic side effects. Because of 
the ageing population and the subsequent rise of joint 
arthroplasties performed, it is expected that chronic 
PJI’s and the number of ‘inoperable patients’ 
increase.6 Therefore, in the following decades, AST 
will probably play a more prominent role in the 
treatment of chronic PJI’s. Patients, as well as treating 
orthopedic surgeons, infectiologists and medical 
microbiologists, should know of the advantages and 
disadvantages of AST. However, scientific data are 
scarce. 
To determine the efficacy and tolerability of AST 
in patients who are treated with AST, we 
retrospectively evaluated our cohort of patients with a 
PJI who were treated according to this regime, in 
order to inform and guide physicians in making a 
balanced treatment decision for their patients. 
Material and Methods 
Data collection  
We retrospectively collected data from the 
period of January 2009 until January 2015 from 
patients with a chronic PJI that were treated with AST 
and followed at the University Medical Center 
Groningen. PJI was diagnosed using the diagnostic 
criteria described by the Infectious Diseases Society of 
America.7 A chronic PJI was defined as symptoms 
that existed for more than 3 weeks. PJI was 
categorized in early (< 3 month after implantation), 
delayed (3 months – 2 years after implantation) and 
late infection (> 2 years after implantation). We 
collected the data by analyzing the reports of our 
weekly multidisciplinary meetings, where all patients 
with a PJI are discussed. Therefore, all subsequent 
patients in our center treated with AST are included in 
the study. AST was defined as antibiotic treatment 
that was started after the standard 3 months of 
‘regular’ antibiotic treatment (in most cases 2 weeks of 
intravenous therapy and 10 weeks of oral therapy). 
The choice for AST was based upon patients’ 
comorbidity, prognosis and the degree of tissue 
vitality and bone stock. The choice for AST was made 
by a multidisciplinary team consisting of orthopedic 
surgeons, infectiologists and medical microbiologists.  
Besides demographic characteristics, we 
collected several patients’ parameters considered to 
be related to outcome; i.e. the patients’ underlying 
disease that led to joint arthroplasty, the affected joint, 
the number of revision surgeries that were performed 
in the affected joint prior to the start of AST, the type 
of prosthesis that was used (i.e. a standard or tumor 
prosthesis), the cultured micro-organisms that were 
accounted as the causative pathogens of the infection, 
the number of surgical debridements and lavages 
before suppression therapy was started and the 
indication reported for AST. We also evaluated the 
degree of inflammation by collecting the C-reactive 
protein (CRP), Erythrocyte Sedimentation Rate (ESR) 
and leucocytes in blood closest around the start of 
AST. 
Outcome; definition of treatment failure 
Treatment was considered as failed, when: 1) the 
patient still reported joint pain during follow-up visits 
at the outpatient clinic, 2) when surgical intervention 
was needed to control the infection (i.e. removal of the 
prosthesis (Girdlestone or arthrodesis), revision 
surgery and/or amputation/dysarticulation) and/or 
3) when death occurred due to the infection.  
Antibiotic treatment and side effects 
The choice for the type of AST was based on the 
cultured micro-organism(s) and its susceptibility 
pattern(s), and the expected (long-term) side effects. 
The antibiotic treatment was advised by the involved 
medical microbiologist and/or infectiologist. If 
micro-organisms were considered as a contaminant 
and were not covered by the chosen antibiotic 
treatment, this was reported. Side effects of antibiotic 
treatment mentioned by patients during outpatient 
clinic visits were collected and noted whether these 
side effects led to dose adjustments, switch of therapy 
and/or discontinuation of treatment.  





Our patients visited the outpatient clinic at 
regular intervals (on average with a 3-6 month 
interval) to evaluate treatment response. When AST 
was successful for a longer time-period and patients 
experienced no side effects, some patients were 
followed by the general practitioner and were 
instructed to contact their treating orthopedic surgeon 
if problems arose. The time of follow-up was defined 
from the time point AST was started. The end-point of 
follow-up of our study was defined as: the patients’ 
last visit at our outpatient clinic and/or orthopedic 
ward during admission, or when treatment failed (as 
described above under: ‘outcome; definition of 
treatment failure’).  
Statistical analysis 
Since multiple variables may affect treatment 
outcome, we considered the number of included 
patients too small in order to perform a multiple 
regression analysis. Therefore, descriptive statistics 
were used to summarize the results. For continuous 
data (i.e. inflammatory parameters), the successful 
and failed treatment group were compared by using 
the Mann-Whitney U-test. All significance tests were 
performed 2-tailed. P-values <0.05 were considered as 
statistically significant. Statistics was performed using 




In the period between January 2009 and January 
2015, 24 patients in our center were started with oral 
AST. We excluded 3 patients from the analysis; 1 
because of patient non-compliance (refused to take 
antibiotic therapy), 1 patient died from another cause 
than infection shortly after AST was started, and 1 
patient was transferred to another hospital and was 
lost to follow-up. In total, 21 patients were included in 
the study. Table 1 shows the patients’ baseline 
characteristics and treatment outcome. The median 
age of the included patients was 67 years (range 21 - 
88). A large proportion of our patients (45%) was 
obese (BMI ≥ 30), 54% were known with coronary 
heart disease, 14% with rheumatoid arthritis and 9% 
with diabetes mellitus. The majority of implants were 
revised prostheses (67%). PJI was caused by the 
following micro-organisms: S. epidermidis (n=6), S. 
aureus (n=6), polymicrobial flora (n=4), P. acnes (n=2), 
S. agalactiae (n=1), S. pyogenes (n=1) and B. fragilis 
(n=1). The median onset of PJI after implantation was 
10 months (range 3-81 months). PJI was classified as 
an early infection in 24%, as a delayed infection in 
33%, and as a late infection in 43% of patients. The 
indication to choose for AST was in 43% of patients 
because of poor bone stock and/or severe tissue 
injury. In most cases this was due to a malignancy or 
several revision surgeries in the past. 48% of patients 
were on AST because of a poor prognosis and/or 
severe comorbidity. In two cases, AST was because of 
patients’ refusal of surgery. 14 of the 21 patients (67%) 
underwent a debridement and/or lavage of the 
affected joint (mean number of procedures per 
patient: 1.5 (± 0.6 SD) before AST was started.  
 
Table 1. Overview of patient characteristics and outcome of antibiotic suppressive therapy (AST).  
Pt 
 






Type of  
prosthesis 
Months after  
implantation 
Surgeries before  




1 M 70 comorbidity osteoarthritis yes hip standard 54 (late) lavage (3) S. pyogenes Successful 
2 M 69 comorbidity/prognosis malignancy yes hip tumor 1 (early) no S. epidermidis Successful 
3 M 40 poor soft tissue malignancy yes hip tumor 1 (early) lavage (1) S. aureus Successful 
4 M 71 prognosis malignancy yes hip standard 1 (early) no S. epidermidis, E.cloacae Successful 
5 F 76 comorbidity osteoarthritis yes knee standard 30 (late)  no S. epidermidis Successful 
6 F 55 comorbidity/prognosis malignancy yes hip standard 1 (early) lavage (1) S. aureus, E. faecalis Successful 
7 F 71 patient wish osteoarthritis yes hip standard 39 (late) lavage (1) Bacteroides fragilis Successful 
8 F 47 poor soft tissue/bone stock osteoarthritis yes hip standard 1 (early) DAIR (1), lavage (1) S. epidermidis (rifampin R) Successful 
9 M 80 comorbidity fracture no shoulder standard 1 (early) lavage (1) P. acnes Successful 
10 M 52 pore bonestock/prognosis malignancy no knee tumor 6 (delayed) DAIR (1) S. aureus Successful 
11 M 35 pore bonestock osteomyelitis yes hip tumor 44 (late) no S. epidermidis Successful 
12 M 21 prognosis malignancy no knee tumor 24 (late) excision sarcoma P. acnes Successful 
13 M 73 poor soft tissue/bone stock fracture yes hip standard 78 (late) DAIR (1), lavage (2) S. aureus Successful 
14 M 88 comorbidity/prognosis osteoarthritis no knee standard 1 (early) lavage (2) S. epidermidis Successful 
15 F 54 poor bonestock RA yes knee tumor 27 (late) no S. aureus Failed 1 
16 M 70 comorbidity/prognosis RA yes knee standard 176 (late) lavage (1) S. aureus Failed 2 
17 F 59 poor soft tissue/bone stock osteoarthritis yes hip tumor 6 (delayed) resposition (3) S. aureus, S. epidermidis Failed 1 
18 F 67 poor soft tissue fracture no shoulder standard 7 (delayed) lavage (2) S. aureus Failed 2 
19 M 58 patient wish malignancy no hip tumor 2 (early) DAIR (2) E.coli (ESBL+), E. faecalis Failed 2 
20 M 68 poor soft tissue fracture no hip tumor 43 (late) DAIR (1), lavage (2) S. agalactiae Failed 3 
21 F 65 comorbidity RA yes hip tumor 9 (delayed) DAIR (1) S. epidermidis Failed 1 
DAIR: debridement, antibiotics, irrigation and retention.  
Definition of failed outcome: 1 surgical intervention needed, 2 death due to persistent prosthetic joint infection, 3 persistent pain. RA: rheumatoid arthritis. 




Treatment outcome and follow-up 
The median follow-up of patients was 21 months 
(range: 3-81). Overall, AST was successful in 67% of 
patients (Table 1). Failure of treatment was due to 
persistent joint pain (n=1), surgical intervention 
because of an uncontrolled infection (n=3), and death 
due the infection (n=3). The number of debridement 
and/or lavage of the affected joint prior to the start of 
AST was approximately equal between the successful 
and failed treatment group (9 out of 14 patients (64%) 
versus 5 out of 7 patients (71%) respectively). Figure 1 
outlines the treatment outcome in association with 
several parameters. In general, we observed a 
treatment success of 90% in patients with a ‘standard’ 
prosthesis (n=11). This success was only 50% in 
patients with a tumor-prosthesis (n=10). Also, 
treatment was successful in 83% of patients with a S. 
epidermidis as causative microorganism for the 
infection. For S. aureus, treatment success was only 
50%. All patients with rheumatoid arthritis (n=3) 
failed on AST. All of these three patients were treated 
with methotrexate or prednisone. In our study, no 
difference in treatment outcome was observed 
between prosthetic knee and hip infections. Patients 
who failed on AST did not have a longer follow-up in 
comparison to patients whose treatment was 
successful (median follow up 15 months versus 27 
months, respectively). Figure 2 shows the treatment 
outcome in relation to inflammatory parameters. The 
median time point of laboratory values around the 
start (day 0) of AST, was +3 days (range -19 to -20 
days). Patients who failed on AST had a higher ESR in 
comparison to patients with a successful treatment 
(mean 73 ± 25SD versus 32 ± 19SD mm/hour (p = 





Figure 1. Outcome of antibiotic suppressive therapy (n=21) subdivided in several parameters; the affected joint (A), the indication for the prosthesis / 
underlying condition (B), the type of prosthesis (C) and the causative pathogen / micro-organism for the prosthetic joint infection (PJI) (D). The definition 
of successful treatment and failed treatment is descripted in the text. 
 
 




Antibiotic suppressive therapy and reported 
side effects 
The ‘regular’ antibiotic treatment, the type of 
AST, the reported side effects and whether these side 
effects led to a change in antibiotic treatment or dose 
adjustments, are shown in Table 2. During the first 
chosen AST regime, nearly half of the patients 
reported side effects (43%), which led to a change in 
treatment in almost all of these patients, from which 
50% was a dose adjustment and 50% a change in 
antibiotic treatment. On the second AST regime, only 
3 out of 8 patients reported side effects. None of these 
3 led to dose adjustments or a change in the antibiotic 
regime. Reported side effects were equal between the 
failed and successful treatment group. Overall, 
clindamycin was best tolerated; side effects were 
reported in only 2 out of 7 patients. Loss of appetite 
improved in one patient after the dose was adjusted to 
300 mg TID. Minocycline was the least tolerated drug. 
Side effects were reported in 4 out of 6 patients, and 
led to a change of treatment or dose adjustment in all 
of these patients. 
Discussion 
With a median follow-up of almost two years, 
we evaluated the efficacy and tolerability of AST in 
patients with a chronic PJI. With an overall treatment 
success of 67% - with the highest success rate 
observed in patients with a ‘standard’ prosthesis and 
a S. epidermidis infection- our data showed that AST is 
a reasonable alternative treatment option for patients 
in whom revision surgery is not feasible or attractive 
because of a variety of reasons. Our treatment success 
is in agreement with previous studies, which report 
success rates between 63%-86%.8-11 Reported success 
rates of >80% in some studies can be explained by the 
inclusion of acute PJI’s, from which it is known that 
retention of the prosthetic joint can be achieved.7  
 
Table 2. Overview of the initial treatment and the antibiotic suppressive therapy (AST) per patient, the reported side effects and subsequent intervention.  
Pt Intravenous  
treatment1 
Oral treatment2 1st AST Side effects 
AST 
Change of  
treatment 







Penicillin 12 mU /day 
 
Amoxicillin 1000 mg TID 
 











2 Vancomycin/day3, 4w Minocycline 100 mg BID Minocycline 100 mg BID Nausea, 
phototoxicity 





Penicillin 12 mU/day 
 
Moxifloxacin 400 mg QD 
Rifampin4 450 mg BID 

















Ciprofloxacin 400 mg TID 
 
 
Ciprofloxacin 750 mg BID 
Rifampin4 450 mg BID 
Linezolid 600 mg BID, 4w 
Mincocyline 100 mg BID, 6w 



























Amoxicillin 12 g/day 
Flucloxacillin 12 g/day 
Gentamicin 3 mg/kg/day 
Amox/clav 500/125 QID 
Rifampin4 450 mg BID 
 



















Metronidazole 500 mg QID 
Amox/clav 750/125 TID 












8 Vancomycin/day3 Mincocyline 100 mg BID Minocycline 100 mg QD No - - - - 
9 
 
Ceftriaxone 2 g QD 
  
Clindamycin 600 mg TID 
Rifampin4 450 mg BID 














Flucloxacillin 12 g/day 
 
Moxifloxacin 400 mg QD 
Rifampin4 450 mg BID 
















Linezolid 600 mg BID, 4w 
Mincocyline 100 mg BID, 8w 














Flucloxacillin 12 g/day 
 
Moxifloxacin 400 mg QD 
Rifampin4 450 mg BID 














Flucloxacillin 12 g/day 
 
Moxifloxacin 400 mg QD 
Rifampin4 450 mg BID 
















Linezolid 600 mg BID, 4w 
Mincocyline 100 mg BID, 6w 

















Flucloxacillin 8 g5/day, 1w 
 












Daptomycin 8 mg/kg/day6 
 
Mincocyline 100 mg BID 
Rifampin4 450 mg BID 














Flucloxacillin 8 g/day5 
 
Moxifloxacin 400 mg QD 
Rifampin4 450 mg BID 















Meropenem 2 g TID 
Vancomycin/day3 
Gentamicin 3 mg/kg/day 
Ciprofloxacin 750 mg BID 
Amoxicillin 1000 mg TID 
 
Cotrimoxazole 960 mg BID 



















Penicillin 12 mU/day, 4w 
Gentamicin 3 mg/kg/day, 4w 
Amoxicillin 1000 mg TID, 8w 
 



















1 Intravenous treatment comprises 2 weeks of treatment, unless otherwise stated. 2 Oral treatment comprises 10 weeks of treatment, unless otherwise stated. 3 The dose of 
vancomycin was determined by therapeutic drug monitoring, aiming towards a serum concentration level of ±25 mg/L (continuous infusion). 4 In general, rifampin is added 
during intravenous treatment after susceptibility is known (after ± 5 days). 5 8 grams of flucloxacillin was chosen because of renal insufficiency. 6 Daptomycin was chosen 
because of allergy to penicillin. 
 






Figure 2. Outcome of antibiotic suppressive therapy (n=21) in relation to 
inflammatory parameters before suppression therapy was started); 
C-reactive protein (CRP) (A), Estimated Sedimentation Rate (ESR) (B), and 
leucocytes (C). The definition of successful treatment and failed treatment 
is descripted in the text. Bars represent the median, the 25th and the 75th 
percentile. 
 
Based on our data, we cannot draw conclusions 
about prognostic factors for treatment success or 
failure. We did observe that treatment succeeded in 
almost all of our patients with a PJI caused by a S. 
epidermidis. This finding may not sound surprising 
since S. epidermidis has low virulence and its natural 
course of infection is often smouldering and 
low-grade in nature. However, Barberan et al. did 
show a 50% relapse rate in patients with a PJI caused 
by coagulase negative staphylococci (CNS) and who 
were treated with a conservative treatment regime 
(i.e. surgical debridement with implant retention and 
a 3 month course of antibiotic treatment). In addition, 
Byren et al. showed that when antibiotic treatment is 
discontinued, even after a long period of suppression 
therapy (with a minimum of 180 days), relapse of 
infection occurs in around 30% of patients.12 
Therefore, long-term antibiotic treatment in patients 
with a PJI due CNS does have additional value to 
suppress the infection, and its favorable outcome is 
not merely due to its natural course. We also observed 
a high success rate in patients with a ‘standard’ 
prosthesis, in comparison with patients with a ‘tumor’ 
prosthesis, in whom 50% of AST failed. In previous 
studies on AST, the type of prosthesis is not 
mentioned. However, it is known, that tumor 
prostheses are more prone to infection in comparison 
to standard prostheses. This may be partly explained 
by poor soft tissue and/or bone stock due to radiation 
therapy, and the larger surface area of a ‘tumor’ 
prosthesis.13 In contrast to other studies, in our cohort 
of patients, we did not observe higher failure rates in 
patients with multiple prior revision surgeries or in 
patients with knee arthroplasties.8  
To our knowledge, we are the first who 
evaluated the degree of inflammation in relation to 
treatment outcome. Although laboratory data were 
not available for every patient shortly before or after 
the start of AST, we believe our results do suggest that 
patients who have an ESR > 65 mm/h when 
suppression therapy is started, probably have a 
higher chance of treatment failure. Our three patients 
with rheumatoid arthritis all failed on AST, two of 
them had an ESR > 65 mm/h. In previous studies, 
rheumatoid arthritis and/or the use of 
immunosuppressive medication has not been 
evaluated as variable for treatment outcome, and 
would be interesting to include as potential 
prognostic factor in future studies.  
Our data give a good impression about the 
challenges patients and treating physicians face 
regarding potential side effects of AST. 43% our 
patients experienced side effect during antibiotic 
therapy. Although the majority of them needed a 
switch of therapy or an alternation of dose, the 
antibiotic treatment was ultimately well tolerated. The 
number of side effects whilst on the ‘first’ antibiotic 
regime is in accordance with the study of Tsukayama 
et al.14 They also report side effects in 38% of patients 
that led to a change in antibiotic therapy. In our study, 
no severe side effects occurred. One previous study 
reported a 22% incidence (4 out of 18 patients) of 
Clostridum difficile infection.15 This high incidence 
might be due to the longer follow-up of this study (at 
least 4 years) or due to the use of a different antibiotic 




treatment regime in the 4 patients with a Clostridium 
infection (2 patients were treated with with 
dicloxacillin).16-17  
In conclusion, for patients with a PJI who are no 
candidate for revision surgery antibiotic suppressive 
therapy seems a reasonable alternative treatment, 
with the highest success rates in patients with a 
standard-prosthesis or with a S. epidermidis infection. 
Although side effects occur frequently, most patients 
finally tolerate treatment after a change in therapy has 
been made. Although numbers are low, antibiotic 
suppressive therapy failed for all our patients with 
rheumatoid arthritis. 
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